§ 35.59 Recentness of training.

The training and experience specified in Subparts B, D, E, F, G, and H of this part must have been obtained within the 7 years preceding the date of application or the individual must have had related continuing education and experience since the required training and experience was completed.

[70 FR 15008, Mar. 27, 2006]

Subpart C—General Technical Requirements

§ 35.60 Possession, use, and calibration of instruments used to measure the activity of unsealed byproduct material.

(a) For direct measurements performed in accordance with §35.63, a licensee shall possess and use instrumentation to measure the activity of unsealed byproduct material before it is administered to each patient or human research subject.

(b) A licensee shall calibrate the instrumentation required in paragraph (a) of this section in accordance with nationally recognized standards or the manufacturer’s instructions.

(c) A licensee shall retain a record of each instrument calibration required by this section in accordance with §35.2060.

§ 35.61 Calibration of survey instruments.

(a) A licensee shall calibrate the survey instruments used to show compliance with this part and 10 CFR Part 20 before first use, annually, and following a repair that affects the calibration. A licensee shall—

(1) Calibrate all scales with readings up to 10 mSv (1000 mrem) per hour with a radiation source;
(2) Calibrate two separated readings on each scale or decade that will be used to show compliance; and
(3) Conspicuously note on the instrument the date of calibration.

(b) A licensee may not use survey instruments if the difference between the indicated exposure rate and the calculated exposure rate is more than 20 percent.

(c) A licensee shall retain a record of each survey instrument calibration in accordance with §35.2061.

§ 35.63 Determination of dosages of unsealed byproduct material for medical use.

(a) A licensee shall determine and record the activity of each dosage before medical use.

(b) For a unit dosage, this determination must be made by—

(1) Direct measurement of radioactivity; or
(2) A decay correction, based on the activity or activity concentration determined by—

(i) A manufacturer or preparer licensed under §32.72 of this chapter or equivalent Agreement State requirements; or
(ii) An NRC or Agreement State licensee for use in research in accordance with a Radioactive Drug Research Committee-approved protocol or an Investigational New Drug (IND) protocol accepted by FDA; or
(iii) A PET radioactive drug producer licensed under §30.32(j) of this chapter or equivalent Agreement State requirements.